A method for delivering an immunotherapy agent to a tumor includes advancing the delivery device into a vessel of a patient, and infusing the agent under pressure into the vessel to penetrate the tumor. The delivery device prevents reflux of the agent toward non-treatment sites.

Various embodiments disclosed relate to drug-coated balloon catheters for treating strictures in body lumens and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent.

The present invention provides a pharmaceutical composition for healing tissue, said pharmaceutical composition comprising adherent cells originating from mesenchymal tissue treated with a physiologically active polypeptide or an LPS, or culture supernatant thereof, and a pharmaceutically acceptable carrier, and a method for producing the pharmaceutical composition.

Implanted extracellular matrix scaffolds used for regenerative medicine generate a highly activated and unique immune response that inhibits tumor formation by T helper cell-macrophage interactions.

The embodiments disclosed herein relate to acellular matrix bioscaffold compositions comprising 1) a natural or synthetic polymer or blend of polymers; 2) collagen I (Col-1); and 3) collagen III (Col-3), wherein the ratio of Col-1 to Col-3 is between 0.5 and 3.5, wherein said bioscaffold is synthetic.

Prosthetic heart valves having a conical shaped base valve structure formed from collagenous mammalian tissue and an expandable stent structure. The base valve structure includes a plurality of elongated ribbon members that are positioned proximate each other in a joined relationship, wherein the elongated ribbon members are positioned adjacent each other and form a plurality of fluid flow modulating regions that open when fluid into and through the base valve structure exhibits a positive pressure relative to the exterior pressure, i.e., a positive pressure differential, wherein the fluid is allowed to be transmitted out of the base valve structure, and transition to a closed configuration when the pressure differential between the interior valve pressure and exterior pressure reduces, wherein the fluid is restricted from flowing out of the base valve structure. The expandable stent structure includes a plurality of tethers adapted to pierce cardiovascular tissue and, thereby, position the base valve structure and, thereby, prosthetic valves formed therewith on said heart valve annulus.

A therapeutic agent which inhibits cytokines and/or inflammatory mediators for use in the treatment of a patient affected by inflammation associated with atherosclerosis and/or a thrombotic state, wherein the treatment includes the local administration of the therapeutic agent in a blood vessel by an intravascular medical device directly at the level of an atherosclerotic plaque, and/or a site of inflammation, and/or a site of a thrombotic phenomenon.

Systems and methods for using microneedle arrays to deliver bioactive compounds are presented. In general, the microneedle array comprises at least three layers: a base layer, a separation layer, and a bioactive layer, wherein the separation layer is situated between the base layer and the bioactive layer. Upon exposure to physiological conditions, the separation layer dissolves and/or disperses, allowing the base layer to be removed while the bioactive layer remains embedded in the outer surface of the skin.

A bioink composition and a 3D bioprinted scar tissue model with the bioink composition closely replicates the physiological and architectural characteristics of naturally occurring scar tissue. The 3D bioprinted scar tissue can be used to test scar resolution treatments among others. Also provided is a method of fabricating the 3D bioprinted scar tissue along with an apparatus for bioprinting the 3D bioprinted scar tissue.

An adipose tissue particle processing system includes a container and a filter screen assembly. The filter screen assembly has a first open end configured to receive adipose tissue from a syringe, and a second closed end opposite to the first open end located in the interior of the container. The filter screen assembly further includes a screen portion between the first open end and the second closed end, the screen portion including a plurality of apertures having diameters selected for processing the adipose tissue received through the first open end into controlled fat aspirate particle sizes that are output through the plurality of apertures into the interior of the container.